ISSN:2167-7964
Journal of Radiology
Open Access
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 551
Indexed In
- Index Copernicus
- Google Scholar
- Open J Gate
- Genamics JournalSeek
- ResearchBible
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- ICMJE
Useful Links
Share This Page
Imaging with new PET tracers in oncology
2nd World Congress on Radiology and Oncology
Alka Chengapa
Apollo Hospitals, India
Posters & Accepted Abstracts: 中国P站 J Radiol
DOI:
Abstract
New PET tracers in oncology-presently 18F-fluorodeoxyglucose (18-F FDG) are the workhorse of PET imaging in Oncology. However, the main disadvantage is its non-specificity. HCC, neuroendocrine tumors, prostate tumors, CNS tumors and renal cell carcinomas may show low or absent FDG uptake. New tracers have been developed to give better sensitivity and specificity. Some are used in clinical practice, while some are still undergoing clinical and pre-clinical trials. Those that are already used for clinical applications include 11C- and 18F-Choline, 11C-Methionine and 18F-FET, 18F-DOPA, 68Ga-DOTA-somatostatin analogues, 11C-acetate and 18F-FLT and 68Ga-PSMA.stu . Other tracers are used in PET not as markers of metabolic activity but as markers of hypoxia inside big neoplastic masses. These compounds (the most important are 18F-MISO, 64Cu-ATSM and 18FEF5) which highlight the presence of hypoxic areas are useful for patients who must be treated with radiotherapy. In fact, it is well known that hypoxia is one the strongest factors associated for treatment resistance and hypoxic areas should be recognized and over-treated compared to non-hypoxic malignant tissues.Biography
